Ms. Lauren P. Silvernail appointed to Nicox Board of Directors

Press Release
Ms. Lauren P. Silvernail appointed to Nicox Board of Directors Renewal of the terms of office of Birgit Stattin Norinder and Michele Garufi

May 17, 2017 - release at 7:30 am CET
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced the appointment of Ms. Lauren P. Silvernail to the Company's Board of Directors, for a period of four years. Ms. Silvernail brings to Nicox more than 30 years of experience in leading business growth and financial strategies for life science companies, including nine years at ISTA Pharmaceuticals, a commercial ophthalmic company that was acquired by Bausch + Lomb in 2012. Ms. Silvernail currently serves as Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc. where she led its 2014 initial public offering and has raised more than $450 million in capital since joining that company.

Today, Nicox also announced that Ms. Birgit Stattin Norinder, already Board member of Nicox since 2011, has been re-elected by the Company's shareholders as a Board member for a period of four years, as well as Michele Garufi to serve another four year term of office.

"Lauren's operational experience in drug development and ophthalmology will complement Nicox' Board of Directors and her deep knowledge of the global financial markets brings transactional expertise that is a welcome addition," said Mr. Garufi, Chairman and Chief Executive Officer of Nicox. "As we prepare for the anticipated potential approvals of VyzultaTM1 and ZERVIATE2 during Q3 2017, Lauren's broad background provides us with valuable expertise as we look to grow and advance our business and expand our globally recognized R&D efforts in ophthalmology. We are delighted to add Lauren's experience in the ophthalmology field and we look forward to her contribution as Nicox continues to grow."

Ms. Silvernail commented: "As a leading R&D company in ophthalmology, and with a rapidly advancing clinical and preclinical pipeline, Nicox is an exciting growth story. I look forward to joining the team to help develop the strategies that will further accelerate the Company's growth."

Prior to Revance Therapeutics, Inc., Ms. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc. where she was a key architect of the company's growth and financing plans, securing over $275 million in financing for the company and culminating in the sale of ISTA to Bausch + Lomb in a $500 million cash transaction. Before that, Ms. Silvernail served in various operating and corporate development positions for Allergan, most recently as Vice President of Business Development. While at Allergan, she led and closed acquisitions, licensing and co-promotion transactions. Earlier in her career, she was a general partner of a seed venture capital fund and led a start-up venture as its first Chief Executive Officer. Prior to that, Ms. Silvernail served in marketing roles at Varian and Bio-Rad Laboratories. She holds an M.B.A. from the University of California, Los Angeles and a B.A. in Biophysics from the University of California at Berkeley.

1. VyzultaTM is the provisionally approved tradename for latanoprostene bunod ophthalmic solution, 0.024%
2. ZERVIATE is the tradename provisionally approved for cetirizine ophthalmic solution, 0.24%
About Nicox
Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: .
Analyst coverage
Bryan, Garnier & Co Hugo Solvet Paris, France
Invest Securities Martial Descoutures Paris, France
Gilbert Dupont Damien Choplain Paris, France
Stifel Christian Glennie London, UK
Upcoming financial and business conferences

May 22-23 BioEquity Europe Paris, France
May 30 Gilbert Dupont 15th Annual Healthcare Conference Paris, France
June 19-22 2017 BIO International Convention San Diego, US
September 25-27 Cantor Fitzgerald's 3rd Annual Healthcare Conference New York; US

Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
Investor Relations
Julien Perez, Valentine Brouchot
T +33 (0)1 44 71 94 94
Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746
United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
Nicolas Merigeau
T +33 (0)1 44 71 94 98
United States
Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99


Source: Nicox